See more : Borders & Southern Petroleum plc (BDRSF) Income Statement Analysis – Financial Results
Complete financial analysis of Iovance Biotherapeutics, Inc. (0JDK.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Iovance Biotherapeutics, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Nihon Kohden Corporation (NHNKY) Income Statement Analysis – Financial Results
- Electrocomponents plc (ECM.L) Income Statement Analysis – Financial Results
- P2 Gold Inc. (PGLDF) Income Statement Analysis – Financial Results
- Unionman Technology Co., Ltd. (688609.SS) Income Statement Analysis – Financial Results
- TruTrace Technologies Inc. (TTTSF) Income Statement Analysis – Financial Results
Iovance Biotherapeutics, Inc. (0JDK.L)
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.76M | 21.14M | 13.98M | 8.71M | 8.12M | 956.00K | 952.00K | 978.00K | 999.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.57M | -21.14M | -13.98M | -8.71M | -8.12M | -956.00K | -952.00K | -978.00K | -999.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -804.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 344.08M | 294.78M | 259.04M | 201.73M | 166.02M | 99.83M | 71.62M | 28.04M | 15.47M | 3.85M | 2.15M | 1.66M |
| General & Administrative | 27.70M | 33.78M | 28.93M | 60.21M | 40.85M | 28.43M | 21.26M | 17.20M | 12.39M | 8.19M | 3.83M | 0.00 |
| Selling & Marketing | 79.22M | -21.14M | -13.98M | -8.71M | -8.12M | -956.00K | -952.00K | 7.43M | -999.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 106.92M | 82.96M | 69.68M | 51.50M | 32.73M | 27.47M | 20.31M | 24.62M | 11.39M | 8.19M | 3.83M | 6.48M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 450.99M | 377.74M | 328.72M | 253.23M | 198.75M | 127.30M | 91.93M | 52.66M | 26.86M | 12.04M | 24.94M | 887.67K |
| Cost & Expenses | 461.75M | 398.88M | 342.70M | 261.94M | 206.87M | 128.26M | 92.88M | 53.64M | 27.86M | 12.04M | 24.94M | 887.67K |
| Interest Income | 13.04M | 2.99M | 451.00K | 2.36M | 9.32M | 3.35M | 832.00K | 671.00K | 200.00K | 6.00K | 445.00K | 2.42M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.55M | 21.14M | 13.98M | 8.71M | 8.12M | 956.00K | 952.00K | 978.00K | 999.00K | 88.00K | 7.00K | 6.21K |
| EBITDA | -449.01M | -374.76M | -328.27M | -250.87M | -189.43M | -127.30M | -91.93M | -43.16M | -26.86M | -11.95M | -24.93M | 508.81K |
| EBITDA Ratio | -37,763.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -460.56M | -398.88M | -342.70M | -261.94M | -206.87M | -128.26M | -92.88M | -53.64M | -27.86M | -12.04M | -5.99M | -8.13M |
| Operating Income Ratio | -38,734.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.04M | 2.99M | 451.00K | 2.36M | 9.32M | 4.68M | 813.00K | 745.00K | 200.00K | 6.00K | -19.40M | 4.82M |
| Income Before Tax | -447.52M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M | -27.66M | -12.04M | -25.38M | -3.31M |
| Income Before Tax Ratio | -37,638.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.48M | 0.00 | 0.00 | -1.00 | 1.00 | 794.86K | 0.00 | 49.45M | 0.00 | 0.00 | 8.46M | 0.00 |
| Net Income | -444.04M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M | -27.66M | -12.04M | -33.84M | -3.31M |
| Net Income Ratio | -37,345.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -3.47 | -4.14 |
| EPS Diluted | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -3.47 | -4.14 |
| Weighted Avg Shares Out | 234.94M | 159.26M | 153.41M | 138.30M | 124.34M | 97.28M | 65.24M | 55.27M | 44.41M | 24.99M | 9.76M | 798.53K |
| Weighted Avg Shares Out (Dil) | 235.13M | 159.26M | 153.41M | 138.30M | 124.34M | 97.28M | 65.24M | 55.27M | 44.41M | 24.99M | 9.76M | 798.53K |
Source: https://incomestatements.info
Category: Stock Reports